<DOC>
	<DOCNO>NCT00867113</DOCNO>
	<brief_summary>This Phase II , non-randomized , open-label , multi-center study conduct USA . The purpose trial evaluate use long term adjuvant imatinib mesylate patient significant risk recurrence follow complete resection primary GIST .</brief_summary>
	<brief_title>Five Year Adjuvant Imatinib Mesylate ( Gleevec® ) Gastrointestinal Stromal Tumor ( GIST )</brief_title>
	<detailed_description>This Phase II , non-randomized , open-label , multi-center study conduct USA . The primary endpoint evaluate use long term adjuvant imatinib mesylate patient significant risk recurrence follow complete resection primary GIST . A total 85 adult patient , 18 year age old enrolled.Participants take 400 mg imatinib mesylate daily mouth total 5 year . At conclusion treatment period , patient follow 2 year survival , status response antineoplastic treatment quality life .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients 18 year age old . 2 . Patient must histological diagnosis primary GIST . 3 . The tumor must express KIT ( CD117 ) protein immunohistochemistry perform central pathology . 4 . Patient must significant risk tumor recurrence define either : Primary GIST ( site ) : ≥ 2 cm mitotic rate ≥ 5/50 HPF 's Nongastric primary GIST : ≥ 5cm 5 . Patient must undergo complete gross resection primary GIST within 12 week prior first dose imatinib study drug . The inclusion R1 resection review case case basis Study Management Committee . 6 . Patient must evidence metastatic GIST either 1 ) postoperative CT abdomen pelvis intravenous oral contrast 2 ) MRI abdomen pelvis intravenous contrast . CT MRI must perform within 8 week prior first dose imatinib study drug . 7 . Performance status 0 1 ( ECOG ) 8 . Patient must follow postoperative laboratory value confirm within 14 day prior first dose imatinib study drug : total bilirubin &lt; 1.5 x ULN NOTE : Patients elevate bilirubin secondary Gilbert 's disease eligible participate study . ALT AST &lt; 2.5 x ULN creatinine &lt; 1.5 x ULN ANC &gt; 1.5 x 109/L platelet &gt; 100 x 109/L 9 . If patient cancer survivor , ALL follow criterion apply : Patient undergone potentially curative therapy prior malignancy . No evidence prior malignancy least 3 year evidence recurrence ( except effectively treat basal cell squamous carcinoma skin , carcinoma insitu cervix effectively treat surgery alone , lobular carcinoma insitu ipsilateral contralateral breast treat surgery alone ) . Patient deem treat physician low risk recurrence prior malignancy . 10 . Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Female patient reproductive potential must agree employ effective barrier method birth control throughout study 7 day follow discontinuation study drug . 11 . Written , voluntary inform consent . 1 . Patient metastatic GIST peritoneum , liver , lymph node , sit recurrent GIST . 2 . Prior treatment GIST exception prior treatment imatinib adjuvant last ≤ 8 week follow gross surgical resection . 3 . Patient receive investigational agent within 28 day first day study drug dose . 4 . Patient Grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) 5 . Patients severe and/or uncontrolled concurrent medical disease opinion investigator could cause unacceptable safety risk compromise compliance protocol ( i.e. , uncontrolled diabetes , chronic renal disease , chronic liver disease , active uncontrolled infection ) . 6 . Patient known diagnosis human immunodeficiency virus ( HIV ) infection . 7 . Patient receive concurrent treatment warfarin ( acceptable alternative : lowmolecular weight heparin ) . 8 . Patient significant history noncompliance medical regimen inability grant reliable informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Imatinib</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Gastrointestinal Stromal Tumors</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>PERSIST</keyword>
	<keyword>PERSIS-5</keyword>
</DOC>